Magnolol elicits activation of the extracellular signal-regulated kinase pathway by inducing p27KIP1-mediated G2/M-phase cell cycle arrest in human urinary bladder cancer 5637 cells

Biochemical Pharmacology

Volumn 75, Issue 12, 2008, Pages 2289-2300

  Lee, Se Jung ^a   Cho, Young Hwa ^b   Park, Keerang ^b   Kim, Eun Jung ^c   Jung, Kyung Hwan ^a   Park, Sung Soo ^d   Kim, Wun Jae ^c   Moon, Sung Kwon ^a  

^a Chungju National University   (South Korea)

^b Juseong College   (South Korea)

^c Chungbuk National University College of Medicine   (South Korea)

^d Cheju Halla University   (South Korea)

Author keywords

Bladder cancer 5637 cells; G2 M phase cell cycle arrest; Magnolol; p27KIP1

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; MAGNOLOL; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38;

ARTICLE; BLADDER CANCER; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; DOWN REGULATION; HUMAN; HUMAN CELL; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BIPHENYL COMPOUNDS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; G2 PHASE; HUMANS; LIGNANS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 44449172525     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.03.022     Document Type: Article

References (39)

1. Raghavan D. Molecular targeting and pharmacogenomics in the management of advanced bladder cancer. Cancer 97 8 Suppl (2003) 2083-2089
2. Cohen S.M., Shirai T., and Steineck G. Epidemiology and etiology of premalignant and malignant urothelial changes. Scand J Urol Nephrol Suppl 205 (2000) 105-115
3. Vineis P., Talaska G., Malaveille C., Bartsch H., Martone T., Sithisarankul P., et al. DNA adducts in urothelial cells: relationship with biomarkers of exposure to arylamines and polycyclic aromatic hydrocarbons from tobacco smoke. Int J Cancer 65 (1996) 314-316
4. Miyajima A., Nakashima J., Yoshioka K., Tachibana M., Tazaki H., and Murai M. Role of reactive oxygen species in cis-dichlorodiammineplatinum-induced cytotoxicity on bladder cancer cells. Br J Cancer 76 (1997) 206-210
5. Heney N.M., Ahmed S., Flanagar M.J., Frable W., Corder M.P., Hafermann M.D., et al. Superficial bladder cancer: progression and recurrence. J Urol 130 (1983) 1083-1086
6. Levi F., La Vecchia C., Randimbison L., and Franceschi S. Incidence of infiltrating cancer following superficial bladder carcinoma. Int J Cancer 55 (1993) 419-554
7. Macleod K.F., Sherry N., Hannon G., Beach D., Tokino T., Kinzler K., et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9 8 (1995) 935-939
8. Jacks T., and Weinberg R.A. Cell-cycle control and its watchman. Nature 381 6584 (1996) 643-644
9. Collins K., Jacks T., and Pavletich N.P. The cell cycle and cancer. Proc Natl Acad Sci USA 94 7 (1997) 2776-2778
10. Sherr C.J. Cancer cell cycles. Science 274 5293 (1996) 1672-1677
11. Nigg E.A. Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. Bioessays 17 (1995) 471-480
12. Gautier J., Solomon M., Booher R., Bazan J., and Kirschner M. Cdc25 is a specific tyrosine phosphatase that directly activates Cdc2. Cell 65 (1991) 197-211
13. Sherr C.J. G1 phase progression: cycling on cue. Cell 79 4 (1994) 551-555
14. Xia Z., Dickens M., Raingeaud J., Davis R.J., and Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270 (1995) 1326-1331
15. Boulton T.G., Nye S.H., Robbins D.J., Ip N.Y., Radziejewska E., Morgenbesser S.D., et al. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 65 (1991) 663-675
16. Segal R., and Greenberg M. Intracellular signaling pathways activated by neurotrophic factors. Annu Rev Neurosci 19 (1996) 463-489
17. Bueno O.F., De Windt L.J., Tymitz K.M., Witt S.A., Kimball T.R., Klevitsky R., et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 19 23 (2000) 6341-6350
18. Remacle-Bonnet M.M., Garrouste F.L., Heller S., Andre F., Marvaldi J.L., and Pommier G.J. Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways. Cancer Res 60 7 (2000) 2007-2017
19. Wang X., Martindale J.L., and Holbrook N.J. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 275 50 (2000) 39435-39443
20. Okano J., and Rustgi A.K. Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery. J Biol Chem 276 22 (2001) 19555-19564
21. Chambard J.C., Lefloch R., Pouyssegur J., and Lenormand P. ERK implication in cell cycle regulation. Biochim Biophys Acta 1773 8 (2007) 1299-1310
22. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Wong E.W., Chang F., et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773 8 (2007) 1263-1284
23. Fanton C.P., McMahon M., and Pieper R.O. Dual growth arrest pathways in astrocytes and astrocytic tumors in response to Raf-1 activation. J Biol Chem 276 (2001) 18871-18877
24. Malumbres M., Pérez De Castro I., Hernández M.I., Jiménez M., Corral T., and Pellicer A. Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15(INK4b). Mol Cell Biol 20 (2000) 2915-2925
25. Liou K.T., Shen Y.C., Chen C.F., Tsao C.M., and Tsai S.K. The anti-inflammatory effect of honokiol on neutrophils: mechanisms in the inhibition of reactive oxygen species production. Eur J Pharmacol 475 (2003) 19-27
26. Teng C.M., Chen C.C., Ko F.N., Lee L.G., Huang T.F., Chen Y.P., et al. Two antiplatelet agents from Magnolia officinalis. Thromb Res 50 (1988) 757-765
27. Lo Y.C., Teng C.M., Chen C.F., Chen C.C., and Hong C.Y. Magnolol and honokiol isolated from Magnolia officinalis protect rat heart mitochondria against lipid peroxidation. Biochem Pharmacol 47 (1994) 549-553
28. Lin S.Y., Liu J.D., Chang H.C., Yeh S.D., Lin C.H., and Lee W.S. Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis. J Cell Biochem 84 3 (2002) 532-544
29. Fong W.F., Tse A.K., Poon K.H., and Wang C. Magnolol and honokiol enhance HL-60 human leukemia cell differentiation induced by 1,25-dihydroxyvitamin D3 and retinoic acid. Int J Biochem Cell Biol 37 2 (2005) 427-441
30. Kim H.M., Bae S.J., Kim D.W., Kim B.K., Lee S.B., Lee U.S., et al. Inhibitory role of magnolol on proliferative capacity and matrix metalloproteinase-9 expression in TNF-alpha-induced vascular smooth muscle cells. Int Immunopharmacol 7 8 (2007) 1083-1091
31. Moon S.K., Jung S.Y., Choi Y.H., Lee Y.C., Patterson C., and Kim C.H. PDTC, metal chelating compound, induces G1 phase cell cycle arrest in vascular smooth muscle cells through inducing p21Cip1 expression: involvement of p38 mitogen activated protein kinase. J Cell Physiol 198 2 (2004) 310-323
32. Moon S.K., Kim H.M., Lee Y.C., and Kim C.H. Disialoganglioside (GD3) synthase gene expression suppresses vascular smooth muscle cell responses via the inhibition of ERK1/2 phosphorylation, cell cycle progression, and matrix metalloproteinase-9 expression. J Biol Chem 279 32 (2004) 33063-33070
33. Genersch E., Hayess K., Neuenfeld Y., and Haller H. Sustained ERK phosphorylation is necessary but not sufficient for MMP-9 regulation in endothelial cells: involvement of Ras-dependent and -independent pathways. J Cell Sci 113 Pt 23 (2000) 4319-4330
34. Auer K.L., Contessa J., Brenz-Verca S., Pirola L., Rusconi S., Cooper G., et al. The Ras/Rac1/Cdc42/SEK/JNK/c-Jun cascade is a key pathway by which agonists stimulate DNA synthesis in primary cultures of rat hepatocytes. Mol Biol Cell 9 3 (1998) 561-573
35. Marshall C. How do small GTPase signal transduction pathways regulate cell cycle entry?. Curr Opin Cell Biol 11 (1999) 732-736
36. Blenis J. Signal transduction via the MAP kinases: Proceed at your own RSK. Proc Natl Acad Sci USA 90 (1993) 5889-5892
37. Blumer K.L., and Johnson G.L. Diversity in function and regulation of MAP kinase pathways. Trends Biochem Sci 19 (1994) 236-240
38. Post G.R., and Brown J.H. G protein-coupled receptors and signaling pathways regulating growth responses. FASEB J 10 (1996) 741-749
39. Hsu Y.F., Lee T.S., Lin S.Y., Hsu S.P., Juan S.H., Hsu Y.H., et al. Involvement of Ras/Raf-1/ERK actions in the magnolol-induced upregulation of p21 and cell-cycle arrest in colon cancer cells. Mol Carcinog 46 4 (2007) 275-283